Eli Lilly’s Retevmo Wins Full FDA Approval, Expanded to More Lung Cancer Patients

The FDA has formally granted full approval to Eli Lilly’s (LLY) RET inhibitor Retevmo (selpercatinib) for adults with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This expands the label from the 2020 accelerated approval, which covered previously treated patients, to a broader first-line population. As of the July 14 close, Lilly shares were at $1,152.54, down 2.48% from the prior close of $1,181.87, with an intraday low of $1,140.74 and a high of $1,166.01. U.S. markets were closed for a holiday on July 15, so no pre-market or intraday changes are available.

Full Approval Based on Phase III Data

The FDA’s full approval is primarily based on results from the Phase III LIBRETTO-431 trial. This global, randomized, open-label study evaluated Retevmo versus standard of care (platinum-based doublet chemotherapy with or without pembrolizumab) in patients with RET fusion-positive advanced NSCLC. The data showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS), meeting the primary endpoint. According to Lilly’s previously disclosed information, Retevmo demonstrated sustained anti-tumor activity in RET fusion-positive NSCLC patients, with a safety profile consistent with prior studies.^[BioSpace]

Retevmo’s Approval History and Market Position

Retevmo first received FDA accelerated approval in May 2020 for adults with metastatic RET fusion-positive NSCLC, as well as for advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive advanced or metastatic thyroid cancer. This full approval solidifies the drug’s regulatory standing in NSCLC. Retevmo was one of the first RET inhibitors approved for RET fusion-positive NSCLC, competing with Blueprint Medicines’ Gavreto (pralsetinib) in this niche. Industry analysis indicates RET fusions occur in about 1-2% of NSCLC patients — a small but targeted population with a clear need for effective therapy.

Lilly’s Oncology Business and Stock Performance

Lilly has been steadily building its oncology pipeline, and Retevmo is a core product in its RET inhibitor portfolio. Beyond NSCLC, Retevmo is also approved for thyroid cancer indications. This full approval is expected to expand Retevmo’s market reach, particularly in the first-line setting. However, Lilly shares fell on July 14, closing at $1,152.54, down 2.48%, with an intraday low of $1,140.74. The stock opened at $1,166.01, hit a high of $1,166.01, and closed at $1,152.54. U.S. markets were closed on July 15 for a holiday, so no trading data is available.

Analyst and Market Reaction

Several Wall Street banks have weighed in on the approval. According to Reuters, analysts generally view the full approval as in line with expectations, but the market’s focus on Lilly’s overall revenue growth remains on its diabetes and obesity drugs (Mounjaro and Zepbound). Some analysts note that the competitive landscape in NSCLC for Retevmo is relatively stable, but full approval helps solidify its market position. Separately, investors are closely watching the approval progress of Lilly’s Alzheimer’s drug donanemab. The consensus is that Retevmo’s full approval will have a limited near-term financial impact on Lilly, but over the long term, it helps diversify its oncology portfolio.

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.